Literature DB >> 33685801

Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media.

Satoshi Hamada1, Eriko Ogino2, Hirotaka Yasuba3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33685801     DOI： 10.1016/j.alit.2021.02.002

Source DB:  PubMed          Journal:  Allergol Int        ISSN： 1323-8930            Impact factor:   5.836


× No keyword cloud information.
  3 in total

1.  Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media.

Authors:  Ayumi Chikumoto; Keiji Oishi; Kazuki Hamada; Tsunahiko Hirano; Tomoyuki Kakugawa; Keiko Kanesada; Kazuto Matsunaga
Journal:  Biomolecules       Date:  2022-03-30

2.  IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma.

Authors:  Hideyasu Shimizu; Masamichi Hayashi; Hisayuki Kato; Mitsuru Nakagawa; Kazuyoshi Imaizumi; Mitsushi Okazawa
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

3.  Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP.

Authors:  Eugenio De Corso; Claudio Montuori; Stefano Settimi; Dario Antonio Mele; Alessandro Cantiani; Marco Corbò; Elena Cantone; Gaetano Paludetti; Jacopo Galli
Journal:  J Clin Med       Date:  2022-02-10       Impact factor: 4.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.